Zacks Investment Research cut shares of SWEDISH ORPHAN/S (OTCMKTS:SWTUY) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine upgraded SWEDISH ORPHAN/S from a hold rating to a buy rating in a report on Thursday, July 19th.
Shares of OTCMKTS SWTUY opened at $21.39 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.57 and a current ratio of 2.00. The firm has a market capitalization of $5.71 billion, a P/E ratio of 42.78, a P/E/G ratio of 2.92 and a beta of 3.01. SWEDISH ORPHAN/S has a 52-week low of $12.55 and a 52-week high of $31.96.
SWEDISH ORPHAN/S Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Further Reading: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.